The Future of Widespread AI Adoption in Drug Discovery: a Comparative Analysis of the United States and the United Kingdom

EasyChair Preprint 15773

Abstract

This study explores the transformative potential of artificial intelligence (AI) in drug discovery, focusing on its ability to enhance traditional methods and improve success rates. A comparative analysis of the United States (US) and the United Kingdom (UK) reveals that the US leads in AI integration due to substantial funding and proactive regulatory frameworks. While the UK has made significant progress, it faces challenges in commercializing AI technologies in drug discovery. The study emphasizes the importance of increased financial support and flexible regulatory frameworks to promote AI-driven advancements in drug discovery.

Keyphrases: Artificial Intelligence., Healthcare advancements, National AI Strategy, deep learning, drug discovery, machine learning, molecule drug discovery

@booklet{EasyChair:15773,
  author    = {Karima Bharati Bayana},
  title     = {The Future of Widespread AI Adoption in Drug Discovery: a Comparative Analysis of the United States and the United Kingdom},
  howpublished = {EasyChair Preprint 15773},
  year      = {EasyChair, 2025}}